26 stories mentioning TEVAUpdated 4d ago
Every FINWIRES story that references TEVA, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Teva Pharmaceutical Industries (TEVA) has an average rating of buy and mean price target of $41.89 according to analysts polled by FactSet.
S&P Global Ratings (SPGI) said Friday it raised its rating on Teva Pharmaceutical (TEVA), including its issuer credit rating and issue-level rating on the company's unsecured debt, to 'BBB-' from 'BB+'.Teva has demonstrated sustainable growth prospects through strong execution in branded products, stabilization in generics, and a pipeline of significant late-stage assets, supporting S&P Global Ratings' view of its earnings durability, at least over the next two years, S&P Global said.
Healthcare stocks were flat to higher premarket Wednesday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.5%.Teva Pharmaceutical Industries (TEVA) shares were up more than 1% after the company said its investigational anti-IL-15 antibody TEV '408 met the primary endpoint in an ongoing Phase 2a study in adults with celiac disease.Telix Pharmaceuticals (TLX) has completed patient enrollment for the phase 3 study of its commercial PSMA-PET imaging agents Illuccix and Gozellix in prostate cancer imaging in pre-biopsy setting, the company said. Telix Pharmaceuticals stock was up more than 5% pre-bell.uniQure (QURE) has submitted a Biologics License Application to the US Food and Drug Administration for the accelerated approval of AMT-130 to treat Huntington's disease, the company said. uniQure shares were up more than 6% premarket.
Health care stocks were flat to higher premarket Wednesday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.4%.Teva Pharmaceutical Industries (TEVA) shares were up more than 4% after the company said its investigational anti-IL-15 antibody TEV '408 met the primary endpoint in an ongoing Phase 2a study in adults with celiac disease.
(Updates to add share movement in the headline and the first paragraph.)Alvotech's (ALVO) shares rose nearly 5% in Monday trading after the company said that its biologics license application for AVT80 as a proposed interchangeable biosimilar to Entyvio was accepted for review by the US Food and Drug Administration.Entyvio is approved as a treatment for adults with moderately to severely active ulcerative colitis and Crohn's disease, according to the statement. The application is backed by data that demonstrate the biosimilarity between AVT80 and Entyvio.AVT80 is under a partnership between Alvotech and Teva Pharmaceutical Industries (TEVA), with Alvotech in charge of development and manufacturing and Teva responsible for commercialization, according to the statement.Price: $5.19, Change: $+0.24, Percent Change: +4.85%
Evan Lippman, Executive Vice President, Business Development, on August 17, 2026, sold 18,600 shares in Teva Pharmaceutical Industries (TEVA) for $680,291. Following the Form 4 filing with the SEC, Lippman has control over a total of 25,591 ordinary shares of the company, with 25,591 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526356853/xslF345X05/ownership.xml
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index rising 3.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 3.6%.The iShares Biotechnology ETF (IBB) climbed 6.3%.In sector news, President Donald Trump said Wednesday he has nominated Heidi Overton as the US Food and Drug Administration Commissioner. "We need her leadership at the FDA now to ensure that the US remains the WORLD LEADER for Scientific Discovery and CURES," Trump said in a post on Truth Social.In corporate news, Moderna (MRNA) shares surged 167% and Merck (MRK) shares jumped past 12% after the companies said a trial of intismeran autogene plus Keytruda met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in people with completely resected stage IIB-IV melanoma.Twist Bioscience (TWST) shares jumped nearly 20% after the company said Anthropic selected it as an independent evaluator for a multi-arm protein design project using AI.Sight Sciences (SGHT) shares climbed past 3% after the company said that the US Food and Drug Administration has updated the TearCare System's indication to include improving meibomian gland function in adult patients with evaporative dry eye disease caused by meibomian gland dysfunction.Teva Pharmaceutical Industries (TEVA) shares rose 2.1% after its US affiliate Teva Pharmaceuticals said Wednesday the US Food and Drug Administration has accepted its new drug application for ecopipam to potentially treat children with Tourette syndrome.
Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index rising 2.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.7%.The iShares Biotechnology ETF (IBB) climbed 4.8%.In sector news, President Donald Trump said Wednesday he has nominated Heidi Overton as the US Food and Drug Administration Commissioner. "We need her leadership at the FDA now to ensure that the US remains the WORLD LEADER for Scientific Discovery and CURES," Trump said in a post on Truth Social.In corporate news, Moderna (MRNA) shares surged 146% and Merck (MRK) shares jumped past 11% after the companies said a trial of intismeran autogene plus Keytruda met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in people with completely resected stage IIB-IV melanoma.Sight Sciences (SGHT) shares jumped past 6% after the company said that the US Food and Drug Administration has updated the TearCare System's indication to include improving meibomian gland function in adult patients with evaporative dry eye disease caused by meibomian gland dysfunction.Teva Pharmaceutical Industries (TEVA) shares rose 1.6% after its US affiliate Teva Pharmaceuticals said Wednesday the US Food and Drug Administration has accepted its new drug application for ecopipam to potentially treat children with Tourette syndrome.
Matthew Shields, Executive Vice President, Global Operations, on June 18, 2026, sold 9,989 shares in Teva Pharmaceutical Industries (TEVA) for $321,547.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526277490/xslF345X05/ownership.xml
Eliyahu Sharon Kalif, Executive Vice President and Chief Financial Officer, on June 11, 2026, sold 106,563 shares in Teva Pharmaceutical Industries (TEVA) for $3,633,308. Following the Form 4 filing with the SEC, Kalif has control over a total of 65,621 ordinary shares of the company, with 65,621 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526271862/xslF345X05/ownership.xml
Alvotech (ALVO) said Monday the US Food and Drug Administration has agreed to review its licensing application for a proposed interchangeable biosimilar to the biologic medicine Entyvio for the treatment of ulcerative colitis and Crohn's disease.The company is responsible for developing, as well as producing the medication, while Teva Pharmaceutical (TEVA) oversees market distribution, the company said.The submission has testing data to provide the biological equivalence between the proposed alternative therapy and the original.A prior trial testing a separate variation of the treatment successfully achieved all primary targets to serve as the core clinical similarity evidence for both formulations.Shares of Alvotech added more than 4% in Monday premarket activity.Price: $3.71, Change: $+0.17, Percent Change: +4.90%
Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index increasing 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.3%.The iShares Biotechnology ETF (IBB) declined 1%.In corporate news, Teva Pharmaceutical Industries' (TEVA) Teva Pharmaceuticals unit said Friday that a real-world study shows Austedo and Austedo XR tablets improved quality of life for Huntington's disease chorea patients and their caregivers. Teva Pharmaceutical shares were up 0.8%.BioCardia (BCDA) said it has received confirmation from the US Food and Drug Administration that its ongoing heart failure trial may support a premarket approval of the CardiAMP Cell Therapy System for the treatment of ischemic heart failure with reduced ejection fraction. BioCardia shares climbed more than 24%.Edesa Biotech (EDSA) said Friday that new data showed that paridiprubart combined with standard of care treatments was associated with a 32% relative reduction in mortality in patients with acute kidney injury and respiratory distress at 28 days. Edesa Biotech shares dropped 22.4%.
Teva Pharmaceutical Industries' (TEVA) Teva Pharmaceuticals unit said Friday that a real-world study shows AUSTEDO tablets and AUSTEDO XR tablets improved quality of life for Huntington's disease chorea patients and their caregivers.Huntington's disease is a fatal neurodegenerative disease characterized by uncontrollable movements as well as behavioral and/or psychological problems, the company said, adding that chorea is one of the most striking physical manifestations of the disease and occurs in about 90% of patients.The survey data found that more than 68% of patients reported chorea affected their social life or emotional well-being, while up to 83% of caregivers reported disruptions to their own daily lives, the company said.After treatment with AUSTEDO or AUSTEDO XR, 60% to 71% of patients reported improvements in quality of life due to better movement control, and as a result, caregivers also reported less impact on their daily lives, the company added.Shares of Teva Pharmaceutical Industries rose nearly 1.4% in Friday's trading.Price: $34.96, Change: $+0.53, Percent Change: +1.54%
Veeva Systems (VEEV) said Wednesday that Teva Pharmaceutical (TEVA) and Germany-based Merck KGaA have committed to use its Vault CRM software globally.Vault CRM is an application for life sciences companies that connects sales, marketing, and medical teams on a single platform, Veeva said.Financial terms of the agreements were not disclosed.Shares of Veeva were up by more than 3% in Wednesday trading.Price: $163.01, Change: $+4.47, Percent Change: +2.82%
Teva Pharmaceutical Industries' (TEVA) marketing authorization application for olanzapine long-acting injectable for the treatment of schizophrenia in adults has been accepted by the European Medicines Agency, the company said Thursday.The drug, named TEV-749, aims to address treatment adherence in real-world settings and contribute to long-term disease management in people living with schizophrenia.The application is supported by an extensive clinical development program, in which the drug demonstrated efficacy, a systemic safety profile, and exposure consistent with oral olanzapine, Teva said.Shares of Teva were down 1.4% in Thursday trading.Price: $33.82, Change: $-0.50, Percent Change: -1.46%
Eliyahu Sharon Kalif, Executive Vice President, Chief Financial Officer, on May 14, 2026, sold 153,251 shares in Teva Pharmaceutical Industries (TEVA) for $5,457,375. Following the Form 4 filing with the SEC, Kalif has control over a total of 172,184 ordinary shares of the company, with 172,184 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526228870/xslF345X05/ownership.xml
Evan Lippman, Executive Vice President, Business Development, on May 14, 2026, sold 41,658 shares in Teva Pharmaceutical Industries (TEVA) for $1,482,367. Following the Form 4 filing with the SEC, Lippman has control over a total of 44,191 ordinary shares of the company, with 44,191 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526228876/xslF345X05/ownership.xml
Richard Daniell, Executive Vice President, Europe Commercial, on May 05, 2026, sold 30,000 shares in Teva Pharmaceutical Industries (TEVA) for $1,062,000. Following the Form 4 filing with the SEC, Daniell has control over a total of 55,755 ordinary shares of the company, with 55,755 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526211833/xslF345X05/ownership.xml
Amir Weiss, Chief Accounting Officer, on May 06, 2026, sold 10,679 shares in Teva Pharmaceutical Industries (TEVA) for $384,444. Following the Form 4 filing with the SEC, Weiss has control over a total of 20,016 ordinary shares of the company, with 20,016 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526211855/xslF345X05/ownership.xml
Mark Sabag, Executive Vice President, International Markets Commercial, on May 01, 2026, sold 144,180 shares in Teva Pharmaceutical Industries (TEVA) for $5,045,118. Following the Form 4 filing with the SEC, Sabag has control over a total of 80,760 ordinary shares of the company, with 80,760 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526203928/xslF345X05/ownership.xml
Showing 1-20 of 26
